Stock Taper
Pulmonx Corporation develops minimally invasive devices like Zephyr Valves and assessment systems for treating severe emphysema, providing diagnostic and treatment solutions globally.

The Zephyr Endobronchial Valve is a minimally invasive device that improves breathing and quality of life for severe emphysema patients by blocking diseased lung areas during a bronchoscopic procedure.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $13.97M | $14.1M ▲ | $13.26M ▼ | $14.18M ▲ |
![]() | EMEA | $6.63M | $7.88M ▲ | $6.57M ▼ | $7.73M ▲ |
![]() | Asia Pacific | $842K | $565K ▼ | $707K ▲ | $726K ▲ |
![]() | Other International Geographical Areas | $68K | $52K ▼ | $51K ▼ | $126K ▲ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
RLMD | $4.38 | COMPARE |
IMUX | $11.96 | COMPARE |
VXRT | $0.50 | COMPARE |
ACRV | $2.08 | COMPARE |
HYPR | $0.83 | COMPARE |
PMVP | $1.22 | COMPARE |
TELA | $0.81 | COMPARE |
TCRX | $0.37 | COMPARE |